1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. DOI: 10.1016/j. diabres.2021.109119.

2. International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels, Belgium; 2021. Available on: https://www.diabetesatlas.org

3. Pelle MC, Provenzano M, Busutti M, Porcu CV, Zaffina I, Stanga L, Arturi F. Up-Date on Diabetic Nephropathy. Life (Basel). 2022;12(8):1202. DOI: 10.3390/life12081202. 

4. Li R, Bilik D, Brown MB, et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care. 2013;19:421–30. Available on: https://pmc. ncbi.nlm.nih.gov/articles/PMC4337403/

5. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect. 1999;1(15):1349-1365. DOI: 10.1016/s1286-4579(99)00250-6.

6. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA. 1993;90:1814-1818. DOI: 10.1073/pnas.90.5.1814.

7. Roberts RB, Heine UI, Flanders KC, Sporn MB. Transforming growth factor-beta. Major role in regulation of extracellular matrix. Ann NY Acad Sci. 1990;580:225-232. DOI: 10.1111/ j.1749-6632.1990.tb17931.x.

8. Jakus V, Sapak M, Kostolanska J. Circulating TGF-beta1, glycation, and oxidation in children with diabetes mellitus type 1. Exp Diabetes Res. 2012;2012:510902. DOI: 10.1155/2012/510902.

9. Shaker YM, Soliman HA, Ezzat E, Hussein NS, Ashour E, Donia A, et al. Serum and urinary transforming growth factor beta 1 as biochemical markers in diabetic nephropathy patients. Beni Suef Univ J Basic Appl Sci. 2014;3:16-23. DOI: 10.1016/j.bjbas.2014.02.002.

10. Hathaway CK, Gasim AM, Grant R, Chang AS, Kim HS, Madden VJ, et al. Low TGFbeta1 expression prevents and high expression exacerbates diabetic nephropathy in mice. Proc Natl Acad Sci USA. 2015;112:5815-5820. DOI: 10.1073/pnas.1504777112.

11. The PRISMA 2020 statement: an updated guide- line for reporting systematic reviews. BMJ. 2021;372:n71. DOI: 10.1136/bmj.n71.

12. Chaudhuri A, Ghanim H, Arora P. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes Obes Metab. 2022;24(3):365-376. DOI: 10.1111/dom.14601.

13. Premaratne E, Verma S, Ekinci EI, Theverkalam G, Jerums G, MacIsaac RJ. The impact of hyperfiltration on the diabetic kidney. Diabetes Metab. 2015;41:5-17. DOI: 10.1016/j. diabet.2014.10.003

14. Gembillo G, Ingrasciotta Y, Crisafulli S, Luxi N, Siligato R, Santoro D, et al. Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia. Int J Mol Sci. 2021;22(9):4824. DOI:10.3390/ijms22094824.

15. Woodhams L, Sim TF, Chalmers L, Yeap B, Green D, Schlaich M, et al. Diabetic kidney disease in type 2 diabetes: A review of pathogenic mechanisms, patient-related factors and therapeutic options. PeerJ. 2021;9:e11070. DOI:10.7717/peerj.11070.

16. Matoba K, Takeda Y, Nagai Y, Yokota T, Utsunomiya K, Nishimura R. Targeting redox imbalance as an approach for diabetic kidney disease. Biomedicines. 2020;8:40. DOI: 10.3390/biomedicines8020040.

17. Stieger N, Worthmann K, Teng B, Engeli S, Das AM, Haller H, et al. Impact of high glucose and transforming growth factor-β on bioenergetic profiles in podocytes. Metabolism.  2012;61(8):1073-86. DOI:1 0.1016/j. metabol.2011.12.003.

18. Suryavanshi S, Kulkarni Y. NF-κB: A potential target in the management of vascular complications of diabetes. Front Pharmacol. 2017;8:798. DOI: 10.3389/fphar.2017.00798.

19. Pasupulati KA, Chitra P, Reddy G. Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy. Biomolecular Concepts. 2016;7(5- 6):293-309. DOI: 10.1515/bmc-2016-0021.

20. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597–605. DOI: 10.1161/CIRCULATIONAHA.106.621854.

21. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl). 2005;83:876–86. DOI: 10.1007/s00109-005-0688-7.

22. Donate-Correa J, Luis-Rodríguez D, Martín Núñez E, Tagua VG, Hernández-Carballo C, Ferri C, et al. Inflammatory Targets in Diabetic Nephropathy. J Clin Med. 2020;9(2):458. DOI: 10.3390/jcm9020458.

23. Jha JC, Banal C, Chow BS, Cooper ME, Jandeleit-Dahm K. Diabetes and Kidney Disease: Role of Oxidative Stress. Antioxid Redox Signal. 2016;25(12):657–84. DOI: 10.1089/ars.2016.6664.

24. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008;57:1446–54. DOI: 10.2337/db08-0057.

25. Persson P, et al. Tubular reabsorption and diabetes-induced glomerular hyperfiltration. Acta Physiol (Oxf). 2010;200(1):3-10. DOI: 10.1111/j.1748-1716.2010.02147.x.

26. Tonneijck L, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28(4):1023- 1039. DOI: 10.1681/ASN.2016060666. 27. Basolo A, Salvetti G, Giannese D, Genzano SB, Ceccarini G, Giannini R, et al. Obesity, Hyperfiltration, and Early Kidney Damage: A New Formula for the Estimation of Creatinine Clearance. J Clin Endocrinol Metab. 2023;108(12):3280-3286. DOI: 10.1210/clinem/ dgad330.

28. Weiss A, Attisano L. The TGFbeta superfamily signaling pathway. Wiley Interdiscip Rev Dev Biol. 2013;2:47-63. DOI: 10.1002/wdev.86. 29. Meng XM, Tang PM, Li J, Lan HY. TGF-beta/ Smad signaling in renal fibrosis. Front Physiol. 2015;6:82. DOI: 10.3389/fphys.2015.00082.

30. Wang L, Wang H, Lan H. TGF-β signaling in diabetic nephropathy: An update. Diabetic Nephropathy. 2022;2(1): 7-16. DOI: 10.2478/ dine-2022-0011.

31. Zhang YE. Non-Smad signaling pathways of the TGF-beta family. Cold Spring Harb Perspect Biol. 2017;9:a022129. DOI: 10.1101/ cshperspect.a022129.

32. Wang L, Wang HL, Liu TT, Lan HY. TGF-Beta as a Master Regulator of Diabetic Nephropathy. Int J Mol Sci. 2021;22(15):7881. DOI: 10.3390/ ijms22157881.

33. Zhao L, Zou Y, Liu F. Transforming Growth Factor-Beta1 in Diabetic Kidney Disease. Front Cell Dev Biol. 2020;8:187. DOI: 10.3389/ fcell.2020.00187.

34. Zhang K, Fan C, Cai D, Zhang Y, Zuo R, Zhu L, et al. Contribution of TGF-Beta-Mediated NLRP3-HMGB1 Activation to Tubulointerstitial Fibrosis in Rat with Angiotensin II-Induced Chronic Kidney Disease. Front Cell Dev Biol. 2020;8:1. DOI: 10.3389/fcell.2020.00001.

35. Humphreys BD. Mechanisms of renal fibrosis. Annu Rev Physiol. 2018;80:309-326. DOI: 10.1146/annurev-physiol-022516-034227. 36. Zhou D, Liu Y. Understanding the mechanisms of kidney fibrosis. Nat Rev Nephrol. 2016;12:68. DOI: 10.1038/nrneph.2015.215.

37. Stangenberg S, Saad S, Schilter HC, Zaky A, Gill A, Pollock CA, et al. Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy. Sci Rep. 2018;8(1):9423. DOI: 10.1038/s41598-018- 27462-6.

38. Mack M, Yanagita M. Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int. 2015;87:297-307. DOI: 10.1038/ ki.2014.287.

39. Chang AS, Hathaway CK, Smithies O, Kakoki M. Transforming growth factor-β1 and diabetic nephropathy. Am J Physiol Renal Physiol. 2016;310(8):F689-F696. DOI: 10.1152/ ajprenal.00502.2015.

40. Xu B-H, Sheng J, You Y-K, Huang X-R, Ma RCW, Wang Q, et al. Deletion of Smad3 prevents renal fibrosis and inflammation in Type 2 diabetic nephropathy. Metab Clin Exp. 2020;103:154013. DOI: 10.1016/j.metabol.2019.154013.

41. Liu R, Das B, Xiao W, Li Z, Li H, Lee K, et al. A novel inhibitor of homeodomain interacting protein kinase 2 mitigates kidney fibrosis through inhibition of the TGF-β1/Smad3 pathway. J Am Soc Nephrol. 2017;28:2133- 2143. DOI: 10.1681/ASN.2016080841.

42. Meng XM, Huang XR, Chung ACK, Qin W, Shao X, Igarashi P, et al. Smad2 protects against TGF-Beta/Smad3-Mediated renal fibrosis. J Am Soc Nephrol. 2010;21:1477-1487. DOI: 10.1681/ASN.2009121244.

43. Meng XM, Huang XR, Xiao J, Chung AC, Qin W, Chen HY, Lan HY. Disruption of Smad4 impairs TGF-beta/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int. 2012;81:266-279. DOI: 10.1038/ ki.2011.327

44. Wang A, Ziyadeh FN, Lee EY, Pyagay PE, Sung SH, Sheardown SA, et al. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol. 2007;293:F1657-65. DOI: 10.1152/ ajprenal.00274.2007.

45. Ka SM, Yeh YC, Huang XR, Chao TK, Hung YJ, Yu CP, et al. Kidney-targeting Smad7 gene transfer inhibits renal TGF-beta/MAD homologue (SMAD) and nuclear factor kappaB (NF-kappaB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia. 2012;55:509-19. DOI: 10.1007/ s00125-011-2364-5.

46. Chen HY, Huang XR, Wang W, Li JH, Heuchel RL, Chung AC, et al. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes. 2011;60:590- 601. DOI: 10.2337/db10-0403.

47. Ding Y, Kim JK, Kim SI, Na HJ, Jun SY, Lee SJ, et al. TGF-β1 protects against mesangial cell apoptosis via induction of autophagy. J Biol Chem. 2010;285(48):37909-19. DOI: 10.1074/ jbc.M109.093724.

48. Livingston MJ, Ding HF, Huang S, Hill JA, Yin XM, Dong Z. Persistent activation of autophagy in kidney tubular cells promotes renal interstitial fibrosis during unilateral ureteral obstruction. Autophagy. 2016;12(7):976-98. DOI: 10.1080/15548627.2016.1166317.

49. Xu Y, Yang S, Huang J, Ruan S, Zheng Z, Lin J. Tgf-β1 induces autophagy and promotes apoptosis in renal tubular epithelial cells. Int J Mol Med. 2012;29(2):781-90. DOI: 10.3892/ ijmm.2012.911.

50. Koesters R, Kaissling B, Lehir M, Picard N, Theilig F, Gebhardt R, et al. Tubular overexpression of transforming growth factor beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol. 2010;177(3):632-43. DOI: 10.2353/ajpath.2010.091012.

51. Kim S, Kang SW, Joo J, et al. Characterization of ferroptosis in kidney tubular cell death under diabetic conditions. Cell Death Dis. 2021;12(2):160. DOI: 10.1038/s41419-021- 03452-x.

52. Kang HM, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015;21:37-46. DOI: 10.1038/nm.3762.

53. Kayhan M, Vouillamoz J, Rodriguez DG, et al. Intrinsic TGF-β signaling attenuates proximal tubule mitochondrial injury and inflammation in chronic kidney disease. Nat Commun. 2023;14(1):3236. DOI: 10.1038/s41467-023- 39050-y.